Neurosense Therapeutics Ltd (NRSN) - Total Assets
Based on the latest financial reports, Neurosense Therapeutics Ltd (NRSN) holds total assets worth $1.68 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Neurosense Therapeutics Ltd book value and equity for net asset value and shareholders' equity analysis.
Neurosense Therapeutics Ltd - Total Assets Trend (2019–2024)
This chart illustrates how Neurosense Therapeutics Ltd's total assets have evolved over time, based on quarterly financial data.
Neurosense Therapeutics Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Neurosense Therapeutics Ltd's total assets of $1.68 Million consist of 96.2% current assets and 3.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 73.8% |
| Accounts Receivable | $164.00K | 3.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Neurosense Therapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Neurosense Therapeutics Ltd (NRSN) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Neurosense Therapeutics Ltd's current assets represent 96.2% of total assets in 2024, an increase from 95.6% in 2019.
- Cash Position: Cash and equivalents constituted 73.8% of total assets in 2024, down from 93.7% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 3.6% of total assets.
Neurosense Therapeutics Ltd Competitors by Total Assets
Key competitors of Neurosense Therapeutics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Neurosense Therapeutics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.71 | 0.46 | 6.38 |
| Quick Ratio | 0.71 | 0.46 | 6.38 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-647.00K | $-1.89 Million | $646.00K |
Neurosense Therapeutics Ltd - Advanced Valuation Insights
This section examines the relationship between Neurosense Therapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 12.82 |
| Latest Market Cap to Assets Ratio | 5.79 |
| Asset Growth Rate (YoY) | 44.0% |
| Total Assets | $4.58 Million |
| Market Capitalization | $26.50 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Neurosense Therapeutics Ltd's assets at a significant premium (5.79x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Neurosense Therapeutics Ltd's assets grew by 44.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Neurosense Therapeutics Ltd (2019–2024)
The table below shows the annual total assets of Neurosense Therapeutics Ltd from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $4.58 Million | +44.05% |
| 2023-12-31 | $3.18 Million | -58.81% |
| 2022-12-31 | $7.71 Million | -32.55% |
| 2021-12-31 | $11.43 Million | +1367.39% |
| 2020-12-31 | $779.00K | -18.43% |
| 2019-12-31 | $955.00K | -- |
About Neurosense Therapeutics Ltd
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical… Read more